Stereotactic body radiation therapy for heart-base tumors in six dogs

Magestro, L. M.; Gieger, Tracy L.; Nolan, Michael W.

doi:10.1016/j.jvc.2018.04.001

Cited by 22 publications

(27 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both interventions have been demonstrated to provide a median survival time (MST) of greater than 2 years . Limited studies show that radiation therapy can provide a long‐term benefit as well . In humans, medical management with conventional cytotoxic chemotherapy has not proven to be efficaciousand no studies evaluating efficacy of chemotherapy have been published in veterinary medicine to date.…”

Section: Introductionmentioning

confidence: 99%

Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011‐2018

Lew

McQuown

Borrego³

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

Heart base tumours (HBT) occur commonly in older, brachycephalic dogs. A presumptive diagnosis is made based on location and appearance of the tumour via echocardiogram. Effective treatment options are limited to surgery (when feasible) or radiation therapy. Benefit of medical management is presently unknown. The goal of this retrospective study was to assess the efficacy and tolerability of toceranib phosphate for dogs with HBT. Twenty-eight dogs with histologically, cytologically confirmed or presumed HBT were evaluated retrospectively. Twenty-seven dogs were treated with single agent toceranib. One dog received combination therapy with concurrent metronomic chemotherapy. This dog was not included in response or survival analysis.Factors assessed included clinical signs, hematologic/biochemical parameters and response to treatment. For the 27 dogs receiving single agent toceranib, an overall response rate of 10% was found. Overall median survival time was 823 days (range, 68-1190 days). The overall response rate for the dogs presenting with metastasis was 28.5%, with a median survival time of 532 days (range, 77-679 days). This was not significantly different than the median survival time of 796 days for dogs who did not present with metastasis. Of the dogs displaying clinical signs at the time of diagnosis, 90% had improvement and 81% had complete resolution of signs after starting toceranib. Toxicity was seen in 54% of dogs with gastrointestinal distress as the most common toxicity but dose reductions were infrequent required. Results demonstrate that toceranib phosphate is a well-tolerated and effective treatment for inoperable canine heart base tumours including dogs with advanced or metastatic disease. K E Y W O R D S canine, chemodectoma, heart base tumour, Palladia, toceranib phosphate

show abstract

Section: Introductionmentioning

confidence: 99%

Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011‐2018

Lew

McQuown

Borrego³

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…But regrowth was observed in 3 dogs at 6, 21, 34 months after completion of radiotherapy [40]. Stereotactic body radiation therapy (SBRT) for heart-base tumors in dogs resulted in median survival day of 408 -751 days [41]. Canine soft tissue dose per fraction daily, resulted in median survival of 1,851 days, but median time to local recurrence was 540 days as compared to other tumors (2, 270 days).…”

Section: Discussionmentioning

confidence: 99%

Comparative Mathematical Radiotherapy of Some Dog and Human Cancers

Saganuwan

2019

Preprint

View full text Add to dashboard Cite

BackgroundCancer is a serious disease in human and canine species and can be managed using surgical, chemotherapeutic, immunotherapeutic and radiotherapeutic interventions. But for radiotherapy, determination of radiotherapeutic doses for speci c cancer treatment is a serious problem both in medical and veterinary oncology. ResultsIn view of this, a number of formulas used in medical oncology has been adopted and applied for determination of effective radiotherapeutic doses especially for dogs. Findings revealed that the formulas could be used to estimate radiotherapeutic doses for a number of cancer diseases in dogs. More so, factors such as age, sex, type of cancer, location of cancer and biological effective dose should be considered. The most relevant formula is BED = nd [1 + (d)/(α/β)] where BED = biologically equivalent dose; d = dose per fraction; α/β = ratio for tumor (10) and n = number of fractions. ConclusionsMetronomic radiotherapy which may be de ned as repetitive exposure of cytotoxic radio-active rays of < 2 Gy at regular and frequent intervals of 10-25 fractions of total 45 Gy may be safer for the treatment of malignancies in dog and human. But BED of 45 60 Gy has cancer control rate of 48 -67%, and 50% probabilities of complications was caused by radiation rays of 54 Gy. Whereas a dose of > 2Gy in 2 fractions may improve quality of life and reduce chronic pain associated with terminal malignancies.

show abstract

“…Cardiac tumors ideally require surgical treatment, with the aim of removing all the neoplastic tissue, and, associated systemic drug therapy [3]. Alternatively, external beam radiotherapy was recently used in a dog affected by chemodectoma [4].…”

Section: Introductionmentioning

confidence: 99%

“…In cases of unremovable lesions, palliative pericardiectomy has usually been recommended in order to avoid any potential cardiac tamponade and consequent pleural effusions [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Pericardial Patch as a Palliative Treatment in Three Dogs Affected by Unresectable Cardiac Tumor

et al. 2019

View full text Add to dashboard Cite

This report is aimed at describing a pericardial patch for unresectable cardiac tumors as a palliative technique to prevent pleural effusion. Each dog underwent the same diagnostic protocol including a cardiological assessment, hematology and biochemistry profile, urinary test, abdominal and heart ultrasonography and chest radiographs. Computed tomography was always performed in order to exclude any potential metastatic lesions. All dogs underwent open pericardiectomy: the pericardium was opened and transposed on the mass according to its shape. Biopsy of the mass was always performed. Histopathological evaluation of the masses described two HAS and one chemodectoma. Chemotherapy protocol includes doxorubicin that was weekly administered. Dogs with HSA survived 65 and 85 days respectively without pleural effusion, while the dog with chemodectoma died after six months for reasons unrelated to the tumor. No evidence of pleural effusion was observed during the heart recheck, monthly performed. Pericardial patch is a potential choice as a palliative treatment for unresectable cardiac tumors. No pleural effusion was seen in three dogs affected by unresectable cardiac tumors.

show abstract

Stereotactic body radiation therapy for heart-base tumors in six dogs

Cited by 22 publications

References 23 publications

Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011‐2018

Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011‐2018

Comparative Mathematical Radiotherapy of Some Dog and Human Cancers

Pericardial Patch as a Palliative Treatment in Three Dogs Affected by Unresectable Cardiac Tumor

Contact Info

Product

Resources

About

Stereotactic body radiation therapy for heart-base tumors in six dogs

Cited by 22 publications

References 23 publications

Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011‐2018

Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011‐2018

Comparative&nbsp;Mathematical&nbsp;Radiotherapy&nbsp;of&nbsp;Some&nbsp;Dog&nbsp;and&nbsp;Human&nbsp;Cancers

Pericardial Patch as a Palliative Treatment in Three Dogs Affected by Unresectable Cardiac Tumor

Contact Info

Product

Resources

About

Comparative Mathematical Radiotherapy of Some Dog and Human Cancers